<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610983</url>
  </required_header>
  <id_info>
    <org_study_id>OBP001</org_study_id>
    <nct_id>NCT04610983</nct_id>
  </id_info>
  <brief_title>Omega-3 Bioavailability From Vegetable-omega-3 Enriched Products</brief_title>
  <official_title>Bioavailability of Omega-3 Long-chain Polyunsaturated Fatty Acids (LCPUFA) From Foods Enriched With Vegetable-encapsulated Omega-3 Oils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Commonwealth Scientific and Industrial Research Organisation, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Science, Technology and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Commonwealth Scientific and Industrial Research Organisation, Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CSIRO's Food Program has developed a novel vegetable-based Omega-3 long-chain polyunsaturated&#xD;
      fatty acid (Omega 3)encapsulant to be used as ingredient in various food products, however,&#xD;
      it is unknown whether the vegetable-based carrier matrix will affect omega-3 bioavailability.&#xD;
      This project aims to compare the bioavailability of omega-3 from two test foods containing&#xD;
      vegetable (cauliflower)-encapsulated algal oil (the &quot;ingredient&quot;) against a control test&#xD;
      product (algal oil gel capsules) across two ethnicities (Australian European vs. Chinese&#xD;
      Singaporean).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Omega-3 long-chain polyunsaturated fatty acids (omega-3) (eicosapentaenoic acid [EPA] and&#xD;
      docosahexaenoic acid [DHA]) is associated with many health benefits including improved brain,&#xD;
      heart, joint and eye health. However, &lt;20% of the world's population consume adequate amounts&#xD;
      of these fatty acids. Individuals who don't consume fish (major dietary omega-3 source) and&#xD;
      particularly vegans/vegetarians are at greatest risk of omega-3 deficiency. Convenient&#xD;
      strategies empowering consumers to increase their omega-3 intake have potential to&#xD;
      significantly impact health outcomes. CSIRO's Food Program has developed a novel&#xD;
      vegetable-based omega-3 encapsulant to be used as ingredient in various food products. Using&#xD;
      algal oil as omega-3 source provides vegan/vegetarian options. However, it is unknown whether&#xD;
      the vegetable-based carrier matrix will affect omega-3 bioavailability. As these products are&#xD;
      intended for global markets, it is also unknown whether ethnic differences may affect omega-3&#xD;
      bioavailability. This project forms part of a larger project aiming to develop sensorially&#xD;
      and culturally acceptable food products that incorporate vegetable-encapsulated omega-3 oils&#xD;
      to assist Australian and Singaporean consumers to achieve their omega-3 LCPUFA intake. This&#xD;
      component of the project aims to compare the bioavailability of omega-3 from two test foods&#xD;
      containing vegetable (cauliflower)-encapsulated algal oil (the &quot;ingredient&quot;) against a&#xD;
      control test product (algal oil gel capsules) across two ethnicities (Australian European vs.&#xD;
      Chinese Singaporean). To achieve this, two clinical trials, following the same protocol, will&#xD;
      be executed in both Australia (Australian European) and Singapore (Chinese Singaporean).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomised, controlled, acute, 3-way cross-over study design will be used</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Plasma Omega-3 Concentration</measure>
    <time_frame>0 Minutes (T0), 120 Minutes (T1), 240 Minutes (T2), 360 Minutes (T3), 480 Minutes (T4) and 1440 Minutes (T5)</time_frame>
    <description>Blood Plasma Omega-3 Concentration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Lifestyle</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control 2 * Gel Encapsulated Algal Oil Capsules (each containing 200mg DHA) Total dose of 400mg DHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 1 - Semi-Solid food matrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vegetable encapsulated algal oil integrated with a semi-solid food product (soup) to deliver 400 mg DHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2 - Solid food matrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vegetable encapsulated algal oil integrated with a solid food product (extruded snack) to deliver 400 mg DHA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental: Control</intervention_name>
    <description>2 x algal oil gel capsules delivering 400mg DHA in total</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental: Treatment 1 - Semi-Solid food matrix</intervention_name>
    <description>Test Food 1: 200g serve soup + &quot;ingredient&quot;</description>
    <arm_group_label>Treatment 1 - Semi-Solid food matrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Treatment 2 - Solid food matrix</intervention_name>
    <description>Test Food 2: 50g serve extruded snack (savoury snack) + &quot;ingredient&quot;</description>
    <arm_group_label>Treatment 2 - Solid food matrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men&#xD;
&#xD;
          -  Age: 21-50 years old&#xD;
&#xD;
          -  BMI 18-27.5 kg/m2&#xD;
&#xD;
          -  Consume less than 2 meals of fatty fish/week&#xD;
&#xD;
          -  Not consume fish oil supplements over the past 3 months&#xD;
&#xD;
          -  Identify as Australian European in ethnicity (Australian with European heritage) for&#xD;
             Australian arm of study&#xD;
&#xD;
          -  Identify as Chinese Singaporean in ethnicity (Singaporean with Chinese heritage) for&#xD;
             Singaporean arm of study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chronic disease - cancer, type 2 diabetes, cardiovascular disease, liver&#xD;
             disease or any condition that may, in the opinion of the principle investigator,&#xD;
             influence the study outcomes (Self reported, no clinical testing will be performed)&#xD;
&#xD;
          -  History of gastrointestinal disease, pancreatic insufficiency, conditions resulting in&#xD;
             fat malabsorption - chronic pancreatitis, cystic fibrosis, coeliac disease, Crohns&#xD;
             disease, gastric bypass surgery, small bowel resection, abnormal thyroid function&#xD;
             (Self reported, no clinical testing will be performed)&#xD;
&#xD;
          -  Bleeding disorders, currently taking anticoagulants or has received anticoagulants&#xD;
             within 28 days of Day 1 of the trial, with the exception of low dose aspirin up to150&#xD;
             mg daily (Self reported)&#xD;
&#xD;
          -  Any medical procedures deemed by the principal investigator to affect study outcomes&#xD;
&#xD;
          -  Known food allergies, hypersensitivity, dietary avoidance or intolerance to the study&#xD;
             foods&#xD;
&#xD;
          -  Taking medications/supplements known to influence lipid metabolism and gastric&#xD;
             emptying&#xD;
&#xD;
          -  On any weight-loss program&#xD;
&#xD;
          -  History of smoking during the 6 months prior to the study (Self reported)&#xD;
&#xD;
          -  Persons considered by the investigator to be unwilling, unlikely or unable to&#xD;
             comprehend or comply with the study protocol&#xD;
&#xD;
          -  History of drug abuse or alcoholism (Self reported)&#xD;
&#xD;
          -  Participation in another research study within 30 days preceding the start of this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bradley L Klingner, BSc</last_name>
    <phone>+61 8 83038818</phone>
    <email>Bradley.Klingner@csiro.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>CSIRO, Health and Biosecurity</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley L Klingner, BSc</last_name>
      <phone>+61 8 83038818</phone>
      <email>Bradley.Klingner@csiro.au</email>
    </contact>
    <contact_backup>
      <last_name>Bianca Benassi Evans, PhD</last_name>
      <phone>+61 8 83038982</phone>
      <email>Bianca.Benassi-Evans@csiro.au</email>
    </contact_backup>
    <investigator>
      <last_name>Welma Stonehouse, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A*STAR</name>
      <address>
        <city>Singapore</city>
        <zip>117599</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ciaran G Forde, PhD</last_name>
      <email>Ciaran_Forde@sifbi.a-star.edu.sg</email>
    </contact>
    <contact_backup>
      <last_name>Pey Sze Teo, PhD</last_name>
      <phone>+65 6407 0497</phone>
      <email>Teo_Pey_Sze@sifbi.a-star.edu.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Ciaran G Forde, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Commonwealth Scientific and Industrial Research Organisation, Australia</investigator_affiliation>
    <investigator_full_name>Bradley Klingner</investigator_full_name>
    <investigator_title>Project Manager and Principal Investigator delegate</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT04610983/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

